Economic information and modeling reportBudget impact model
Budget impact model discussion
1 evidence topic · 8 sources
Summary: inputs a vonaprument budget impact model would require
No budget impact model of vonaprument exists. A U.S. payer model would require four inputs that are not yet available: a price (none announced), efficacy and discontinuation data from ARCHER II, the labeled dosing frequency (ARCHER II tests monthly vonaprument 5.0 mg per eye), and the eligible population defined by an approved indication.
Comparator inputs exist for the two complement inhibitors already approved in the United States. October to December 2026 Medicare Part B payment limits were $135.267 per 1 mg of pegcetacoplan (J2781, an AMP-based payment limit) and $100.563 per 0.1 mg of avacincaptad pegol (J2782); launch list prices in 2023 were $2,190 and $2,100 per vial. Medicare Part B spending in 2025 was $451.1 million for Syfovre (32,021 beneficiaries; $2,679 per claim) and $364.9 million for Izervay (27,497 beneficiaries; $2,593 per claim), compared with $403.9 million (29,338 beneficiaries) and $190.4 million (18,308 beneficiaries) in 2024. The 2026 national non-facility Medicare payment for an intravitreal injection (CPT 67028) was $114.23. The manufacturer estimates that approximately 75,000 U.S. patients are actively treated with available therapies, about 10% of the 800,000 diagnosed with GA or under the care of retina specialists and about 5% of an estimated 1.5 million U.S. patients with GA.
The two Australian PBAC financial estimates illustrate the structure such a model would take: an epidemiological approach, a prevalence of 1.29% (pegcetacoplan, aged 60 years and older) or 0.52% (avacincaptad pegol, aged 50 years and older), the proportion with non-subfoveal GA (31.60% for avacincaptad pegol), an uptake curve, injections per year, and administration costs, over 6 years. Both estimates were sensitive to dosing frequency: the PBAC revised pegcetacoplan from 4.5 to 5.39 scripts per year, and for avacincaptad pegol the evaluation tested scenarios in which 50% or 100% of patients continued monthly dosing after year 1, after which the estimated year 6 cost was $70 million to < $80 million, compared with $60 million to < $70 million in the submission. The evaluation of avacincaptad pegol stated that market share calculations would be necessary if pegcetacoplan were listed, a consideration that would also apply to a third agent.